Privium Fund Management B.V. Has $5.45 Million Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Privium Fund Management B.V. raised its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 17.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 294,800 shares of the biotechnology company’s stock after purchasing an additional 43,820 shares during the period. Rocket Pharmaceuticals accounts for about 1.4% of Privium Fund Management B.V.’s investment portfolio, making the stock its 21st largest position. Privium Fund Management B.V. owned approximately 0.32% of Rocket Pharmaceuticals worth $5,445,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in RCKT. Westfield Capital Management Co. LP raised its holdings in shares of Rocket Pharmaceuticals by 1.1% during the 1st quarter. Westfield Capital Management Co. LP now owns 3,984,030 shares of the biotechnology company’s stock valued at $107,330,000 after purchasing an additional 42,171 shares in the last quarter. Maverick Capital Ltd. raised its holdings in Rocket Pharmaceuticals by 1.0% during the second quarter. Maverick Capital Ltd. now owns 3,928,312 shares of the biotechnology company’s stock valued at $84,577,000 after buying an additional 40,000 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Rocket Pharmaceuticals by 11.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,943,160 shares of the biotechnology company’s stock worth $79,290,000 after buying an additional 314,086 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of Rocket Pharmaceuticals by 174.3% in the first quarter. Janus Henderson Group PLC now owns 2,606,016 shares of the biotechnology company’s stock worth $70,170,000 after buying an additional 1,656,111 shares during the last quarter. Finally, Novo Holdings A S boosted its stake in shares of Rocket Pharmaceuticals by 4.8% during the 2nd quarter. Novo Holdings A S now owns 1,100,000 shares of the biotechnology company’s stock worth $23,683,000 after acquiring an additional 50,000 shares in the last quarter. 98.39% of the stock is currently owned by institutional investors and hedge funds.

Rocket Pharmaceuticals Price Performance

Shares of RCKT stock opened at $17.45 on Friday. The company has a market capitalization of $1.59 billion, a P/E ratio of -6.35 and a beta of 1.09. The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 0.05. Rocket Pharmaceuticals, Inc. has a 12 month low of $15.98 and a 12 month high of $32.53. The stock has a 50 day moving average of $18.04 and a two-hundred day moving average of $20.42.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Canaccord Genuity Group reissued a “buy” rating and issued a $38.00 price objective on shares of Rocket Pharmaceuticals in a research note on Monday, September 30th. Scotiabank started coverage on shares of Rocket Pharmaceuticals in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $50.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price objective on shares of Rocket Pharmaceuticals in a report on Tuesday, August 6th. Chardan Capital reiterated a “buy” rating and issued a $62.00 target price on shares of Rocket Pharmaceuticals in a research note on Tuesday, August 6th. Finally, Needham & Company LLC reissued a “buy” rating and set a $52.00 target price on shares of Rocket Pharmaceuticals in a research report on Friday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, Rocket Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $51.75.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.